Next Level Wealth Planning’s Monte Rosa Therapeutics GLUE Stock Holding History

Next Level Wealth Planning’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.09K	Buy	+175	New	+$3K	﹤0.01%	457

Other funds holding GLUE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Next Level Wealth Planning's GLUE Position: Q3 2026 in Review

Next Level Wealth Planning opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 175 shares worth $2.09K. The stake represents ﹤0.01% of the portfolio and ranks #457 among its holdings.

52 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Next Level Wealth Planning held 175 shares of Monte Rosa Therapeutics worth $2.09K as of Q3 2026.
Monte Rosa Therapeutics was a new Next Level Wealth Planning position in Q3 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Next Level Wealth Planning's portfolio in Q3 2026, its #457 holding.
52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Next Level Wealth Planning's 13F filing for Q3 2026, filed 29 Oct 2026.